{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:00:12Z","timestamp":1794859212514,"version":"4.9.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,15]]},"abstract":"<jats:p>There is no generally established prognostic index for patients with mantle cell lymphoma (MCL), because the International Prognostic Index (IPI) and Follicular Lymphoma International Prognostic Index (FLIPI) have been developed for diffuse large cell and follicular lymphoma patients, respectively. Using data of 455 advanced stage MCL patients treated within 3 clinical trials, we examined the prognostic relevance of IPI and FLIPI and derived a new prognostic index (MCL international prognostic index, MIPI) of overall survival (OS). Statistical methods included Kaplan-Meier estimates and the log-rank test for evaluating IPI and FLIPI and multiple Cox regression for developing the MIPI. IPI and FLIPI showed poor separation of survival curves. According to the MIPI, patients were classified into low risk (44% of patients, median OS not reached), intermediate risk (35%, 51 months), and high risk groups (21%, 29 months), based on the 4 independent prognostic factors: age, performance status, lactate dehydrogenase (LDH), and leukocyte count. Cell proliferation (Ki-67) was exploratively analyzed as an important biologic marker and showed strong additional prognostic relevance. The MIPI is the first prognostic index particularly suited for MCL patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL.<\/jats:p>","DOI":"10.1182\/blood-2007-06-095331","type":"journal-article","created":{"date-parts":[[2007,10,25]],"date-time":"2007-10-25T19:36:31Z","timestamp":1193340991000},"page":"558-565","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":838,"title":["A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma"],"prefix":"10.1182","volume":"111","author":[{"given":"Eva","family":"Hoster","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, and"},{"name":"Department of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Lymph Node Registry, University of Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[{"name":"Department of Hematology, H\u00f4pital Saint Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achiel","family":"van Hoof","sequence":"additional","affiliation":[{"name":"Department of Hematology, Akademisch Ziekenhuis St-Jan, Bruges, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Saarland University Medical School, Homburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Metzner","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Peter","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Carl-Thiem Hospital, Cottbus, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of G\u00f6ttingen, G\u00f6ttingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"W\u00f6rmann","sequence":"additional","affiliation":[{"name":"St\u00e4dtisches Klinikum Braunschweig, Braunschweig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Dieter","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Helios Klinikum Berlin-Buch, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Eimermacher","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Wandt","sequence":"additional","affiliation":[{"name":"Medical Department 5, Klinikum N\u00fcrmberg Nord, Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111812063474700_B1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0959-8049(01)00366-5","article-title":"A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors.","volume":"38","author":"Andersen","year":"2002","journal-title":"Eur J Cancer"},{"key":"2019111812063474700_B2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1996.14.4.1269","article-title":"Mantle-cell lymphoma: a population-based clinical study.","volume":"14","author":"Velders","year":"1996","journal-title":"J Clin Oncol"},{"key":"2019111812063474700_B3","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.","volume":"89","year":"1997","journal-title":"Blood"},{"key":"2019111812063474700_B4","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle cell lymphoma: a clinicopathologic study of 80 cases.","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"2019111812063474700_B5","first-page":"29","article-title":"Cytological and functional criteria for the classification of malignant lymphomata.","volume":"31","author":"Lennert","year":"1975","journal-title":"Br J Cancer"},{"key":"2019111812063474700_B6","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.","volume":"49","year":"1982","journal-title":"Cancer"},{"key":"2019111812063474700_B7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","article-title":"Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data.","volume":"16","author":"Banks","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"2019111812063474700_B8","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"2019111812063474700_B9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma.","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"2019111812063474700_B10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/10428199709050890","article-title":"Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 cases.","volume":"26","author":"Decaudin","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"2019111812063474700_B11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"2019111812063474700_B12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0959-8049(97)10056-9","article-title":"Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients.","volume":"34","author":"Oinonen","year":"1998","journal-title":"Eur J Cancer"},{"key":"2019111812063474700_B13","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","article-title":"Mantle cell lymphoma: a retrospective study of 121 cases.","volume":"12","author":"Samaha","year":"1998","journal-title":"Leukemia"},{"key":"2019111812063474700_B14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B","article-title":"Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group.","volume":"64","author":"Weisenburger","year":"2000","journal-title":"Am J Hematol"},{"key":"2019111812063474700_B15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0609.2002.01677.x","article-title":"Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma.","volume":"69","author":"R\u00e4ty","year":"2002","journal-title":"Eur J Haematol"},{"key":"2019111812063474700_B16","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/sj.leu.2403387","article-title":"Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome.","volume":"18","author":"Schrader","year":"2004","journal-title":"Leukemia"},{"key":"2019111812063474700_B17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111812063474700_B18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"2019111812063474700_B19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index.","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"2019111812063474700_B20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.2006.05970.x","article-title":"Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index.","volume":"133","author":"M\u00f8ller","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111812063474700_B21","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","article-title":"Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.","volume":"107","author":"Nickenig","year":"2006","journal-title":"Cancer"},{"key":"2019111812063474700_B22","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111812063474700_B23","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"2019111812063474700_B24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group.","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2019111812063474700_B25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/sim.2331","article-title":"Dichotomizing continuous predictors in multiple regression: a bad idea.","volume":"25","author":"Royston","year":"2006","journal-title":"Stat Med"},{"key":"2019111812063474700_B26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model.","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"key":"2019111812063474700_B27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals.","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"2019111812063474700_B28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/biomet\/77.1.147","article-title":"Martingale-based residuals for survival models.","volume":"77","author":"Therneau","year":"1990","journal-title":"Biometrika"},{"key":"2019111812063474700_B29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","article-title":"Dangers of using \u201coptimal\u201d cutpoints in the evaluation of prognostic factors.","volume":"86","author":"Altman","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"2019111812063474700_B30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1037\/h0026256","article-title":"Weighted Kappa: nominal scale agreement with provision for scaled disagreement or partial credit.","volume":"70","author":"Cohen","year":"1968","journal-title":"Psychol Bull"},{"key":"2019111812063474700_B31","doi-asserted-by":"crossref","DOI":"10.1201\/9780429246593","article-title":"An Introduction to the Bootstrap.","author":"Efron","year":"1994"},{"key":"2019111812063474700_B32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0895-4356(01)00341-9","article-title":"Internal validation of predictive models: efficiency of some procedures for logistic regression analysis.","volume":"54","author":"Steyerberg","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"2019111812063474700_B33","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests.","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"},{"key":"2019111812063474700_B34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1005733404976","article-title":"Validation of existing and development of new prognostic classification schemes in node negative breast cancer.","volume":"42","author":"German Breast Cancer Study Group","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"2019111812063474700_B35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.323.7306.224","article-title":"Systematic reviews of evaluations of prognostic variables.","volume":"323","author":"Altman","year":"2001","journal-title":"BMJ"},{"key":"2019111812063474700_B36","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score.","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"2019111812063474700_B37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/asheducation-2006.1.295","article-title":"Optimal use of prognostic factors in non-Hodgkin lymphoma.","author":"Sehn","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/2\/558\/1220068\/zh800208000558.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/2\/558\/1220068\/zh800208000558.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T08:17:18Z","timestamp":1587975438000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/2\/558\/103675\/A-new-prognostic-index-MIPI-for-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,15]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-06-095331","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,15]]}}}